Trademarkia Logo

Canada

C$
Trademark Search in Canada
VIVITIDE

View On IC.GC.CA

VIVITIDE
REGISTERED

on 16 Apr 2025

Last Applicant/ Owned by

Biosynth International, Inc.

65 Zub LaneGardner, MA 01440

US

Serial Number

2058776 filed on 21st Oct 2020

Registration Number

TMA1306349 registered on 16th Apr 2025

Registration expiry Date

16th Apr 2035

Correspondent Address

DENTONS CANADA LLP

99 BANK STREETSUITE 1420OTTAWA

ONTARIO

CA

K1P1H4

VIVITIDE

Trademark usage description

biochemicals, chemical preparations and diagnostic preparations for in vitro and in vivo use in scientific and laboratory research and development, na Read More

Classification Information

Class [001]
Biochemicals, chemical preparations and diagnostic preparations for in vitro and in vivo use in scientific and laboratory research and development, namely amino acids, amino acid derivatives, antibodies, cytokines, enzyme inhibitors and substrates, growth factors, peptides, reagents for peptide synthesis, and recombinant proteins; chemical additives for use in the manufacture of pharmaceuticals

Classification kind code

11

Class [005]
Chemical preparations for pharmaceutical or medical purposes, namely for preventing or treating Alzheimer's disease, acromegaly, cancer, coronary syndromes, diabetes, diseases of the intestines, endometriosis, erectile dysfunction, glaucoma, growth hormone deficiency, hypoglycemia, myocardial infarction, Parkinson's disease, neurological diseases, rheumatic diseases, microbial diseases, virus infections and skin diseases; diagnostic preparations for medical purposes for detecting Alzheimer's disease, acromegaly, cancer, coronary syndromes, diabetes, diseases of the intestines, endometriosis, erectile dysfunction, glaucoma, growth hormone deficiency, hypoglycemia, myocardial infarction, Parkinson's disease, neurological diseases, rheumatic diseases, microbial diseases, virus infections and skin diseases; diagnostic preparations for veterinary purposes for detecting biomarkers; pharmaceutical preparations for preventing or treating Alzheimer's disease, acromegaly, cancer, coronary syndromes, diabetes, diseases of the intestines, endometriosis, erectile dysfunction, glaucoma, growth hormone deficiency, hypoglycemia, myocardial infarction, Parkinson's disease, neurological diseases, rheumatic diseases, microbial diseases, virus infections and skin diseases; veterinary vaccines; human vaccines

Classification kind code

11

Class [035]
Distributorship services provided through mail order and online catalogs featuring biochemicals, chemical preparations and diagnostic preparations namely, custom peptides, amino acid derivatives, enzyme inhibitors and substrates, and antibodies; mail order and online catalog ordering services featuring biochemicals, chemical preparations and diagnostic preparations namely peptides, amino acid derivatives, enzyme inhibitors and substrates, and antibodies for use by research institutions and pharmaceutical companies

Classification kind code

11

Class [040]
Custom manufacture of peptides and antibodies for research institutions and pharmaceutical companies

Classification kind code

11

Class [042]
Consulting, research, development and analytical services in the field of pharmaceutical development; custom design and development of peptides and antibodies for research institutions and pharmaceutical companies

Classification kind code

11

Mark Details

Serial Number

2058776

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 22
on 9th Sept 2024		Search Recorded
Submitted for opposition 20
on 9th Sept 2024		Examiner's First Report
Submitted for opposition 135
on 4th Aug 2023		Amendment to Application
Submitted for opposition 135
on 2th Aug 2023		Amendment to Application
Submitted for opposition 48
on 1st Aug 2023		Agent Changed
Submitted for opposition 135
on 1st Aug 2023		Amendment to Application
Submitted for opposition 287
on 21st Jun 2022		Pre-Assessment Letter Sent
Submitted for opposition 30
on 21st Oct 2020		Filed
Submitted for opposition 1
on 21st Oct 2020		Created
Submitted for opposition 31
on 21st Oct 2020		Formalized